Pharmaceutical preparations for the treatment of metabolic diseases and orphan diseases, namely, overactivation of insulin receptor by insulin or insulin-like substances, including congenital hyperinsulinism, tumor hyperinsulinism caused by insulinomas and non-islet cell tumors (IGF-2 mediated), transient hypoglycemia (e.g., perinatal stress or related causes), post-bariatric hyperinsulinism (PBHI), post-gastrectomy hyperinsulinism, nesidioblastosis, activating insulin receptor autoantibodies, insulin autoimmune syndrome (IAS), Hirata's disease, monogenic diabetes

'-2':39 'activ':59 'autoantibodi':62 'autoimmun':64 'bariatr':51 'caus':29,48 'cell':36 'congenit':25 'diabet':71 'diseas':8,11,69 'e.g':43 'gastrectomi':56 'hirata':67 'hyperinsulin':26,28,52,57 'hypoglycemia':42 'ia':66 'igf':38 'includ':24 'insulin':15,18,21,60,63 'insulin-lik':20 'insulinoma':31 'islet':35 'like':22 'mediat':40 'metabol':7 'monogen':70 'name':12 'nesidioblastosi':58 'non':34 'non-islet':33 'orphan':10 'overactiv':13 'pbhi':53 'perinat':44 'pharmaceut':1 'post':50,55 'post-bariatr':49 'post-gastrectomi':54 'prepar':2 'receptor':16,61 'relat':47 'stress':45 'substanc':23 'syndrom':65 'transient':41 'treatment':5 'tumor':27,37

Pharmaceutical research and development services

'develop':4 'pharmaceut':1 'research':2 'servic':5

AYMHY

Owner

Goods & Services